The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension
Open accessAbstract
The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown. COVID-19 patients with hypertension were enrolled to evaluate the effect of RAS inhibitors. We observed that patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level of IL-6 in peripheral blood. In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in peripheral blood and decreased the peak viral load compared to other antihypertensive drugs. This evidence supports the benefit of using ACEIs or ARBs to potentially contribute to the improvement of clinical outcomes of COVID-19 patients with hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistent with animal models, it was reported that AngII–AT1R axis inhibitors may be beneficial for COVID-19 patients (360–363) to decrease serum IL-6 levels (360).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [360]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Self-citationWu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445
Self-citationLiu, Y., Yang, Y., Zhang, C., Huang, F., Wang, F., Yuan, J., Wang, Z., Li, J., Li, J., Feng, C., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1643-8 · Cited by 2,056
Self-citationStatus of Hypertension in China: Results From the China Hypertension Survey, 2012–2015
Wang, Z., Chen, Z., Zhang, L., Wang, X., Hao, G., Zhang, Z., Shao, L., Tian, Y., Dong, Y., Zheng, C., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032380 · Cited by 1,698
Self-citationAddendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2951-z · Cited by 715
Self-citationAngiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury
Yang, P., Gu, H., Zhao, Z., Wang, W., Cao, B., Lai, C., Yang, X., Zhang, L., Duan, Y., Zhang, S., et al. (2014) · Scientific Reports · doi:10.1038/srep07027 · Cited by 283
Ye, R., & Liu, Z. (2019) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2019.104350 · Cited by 205
Gage, J. R., Fonarow, G. C., Hamilton, M. A., Widawski, M., Martı́nez-Maza, O., & Vredevoe, D. L. (2004) · NeuroImmunoModulation · doi:10.1159/000076766 · Cited by 81
Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension
Moon, J.-Y. (2013) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2013.11.2.41 · Cited by 81
Research works printed but not linked: 1
- Moon JY. Recent Update of renin-angiotensin-aldosterone. Sys Pathogenesis Hypertens. 2013;11(2):41–45.
Cited by
Sorted by citations
IL-6 in inflammation, autoimmunity and cancer
Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
Reynolds, H. R., Adhikari, S., Pulgarin, C., Troxel, A. B., Iturrate, E., Johnson, S. B., Hausvater, A., Newman, J. D., Berger, J. S., Bangalore, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2008975 · Cited by 1,068
COVID-19 and Multiorgan Response
Zaim, S., Chong, J. H., Sankaranarayanan, V., & Harky, A. (2020) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2020.100618 · Cited by 1,054
COVID-19 in people with diabetes: understanding the reasons for worse outcomes
Apicella, M., Campopiano, M. C., Mantuano, M., Mazoni, L., Coppelli, A., & Prato, S. D. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30238-2 · Cited by 949
Collider bias undermines our understanding of COVID-19 disease risk and severity
Griffith, G. J., Morris, T. T., Tudball, M. J., Herbert, A., Mancano, G., Pike, L., Sharp, G. C., Sterne, J., Palmer, T. M., Davey Smith, G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19478-2 · Cited by 826
The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management
Abou-Ismail, M. Y., Diamond, A., Kapoor, S., Arafah, Y., & Nayak, L. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.06.029 · Cited by 694
How COVID-19 induces cytokine storm with high mortality
Hojyo, S., Uchida, M., Tanaka, K., Hasebe, R., Tanaka, Y., Murakami, M., & Hirano, T. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-020-00146-3 · Cited by 663
SARS-CoV-2 detection, viral load and infectivity over the course of an infection
Walsh, K. A., Jordan, K., Clyne, B., Rohde, D., Drummond, L., Byrne, P., Ahern, S., Carty, P. G., O’Brien, K. K., Murchú, É. Ó., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.06.067 · Cited by 603
Bajaj, V., Gadi, N., Spihlman, A. P., Wu, S. C., Choi, C. H., & Moulton, V. R. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.571416 · Cited by 476
Drug repurposing approach to fight COVID-19
Singh, T. U., Parida, S., Lingaraju, M. C., Kesavan, M., Kumar, D., & Singh, R. K. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00155-6 · Cited by 490
Fang, X., Shen, L., Yu, H., Wang, P., Zhang, Y., Chen, Z., Li, Y., Cheng, L., Li, W., Jia, H., et al. (2020) · Aging · doi:10.18632/aging.103579 · Cited by 492
COVID-19 cytokine storm: the anger of inflammation
Mahmudpour, M., Roozbeh, J., Keshavarz, M., Farrokhi, S., & Nabipour, I. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155151 · Cited by 461
Shi, Q., Zhang, X., Jiang, F., Zhang, X., Hu, N., Bimu, C., Feng, J., Yan, S. Y., Guan, Y., Xu, D., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0598 · Cited by 422
Self-citationProbiotics, prebiotics and synbiotics: Safe options for next-generation therapeutics
Yadav, M. K., Kumari, I., Singh, B., Sharma, K. K., & Tiwari, S. K. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11646-8 · Cited by 454
Gao, C., Cai, Y., Zhang, K., Zhou, L., Zhang, Y., Zhang, X., Li, Q., Li, W., Yang, S., Zhao, X., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa433 · Cited by 421
de Almeida-Pititto, B., Dualib, P. M., Zajdenverg, L., Dantas, J. R., de Souza, F. D., Rodacki, M., Bertoluci, M. C., & Brazilian Diabetes Society Study Group (SBD) (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00586-4 · Cited by 391
Cytokine Storm in COVID-19: Immunopathogenesis and Therapy
Zanza, C., Romenskaya, T., Manetti, A. C., Franceschi, F., Russa, R. L., Bertozzi, G., Maiese, A., Savioli, G., Volonnino, G., & Longhitano, Y. (2022) · Medicina · doi:10.3390/medicina58020144 · Cited by 413
Lópes, R. D., Macedo, A. V. S., Silva, P. G. M. D. B. E., Moll-Bernardes, R. J., dos Santos, T. M., Barbosa, L. M., Feldman, A., Arruda, G., de Albuquerque, D. C., Camiletti, A. S., et al. (2021) · JAMA · doi:10.1001/jama.2020.25864 · Cited by 374
Blood type and outcomes in patients with COVID-19
Latz, C. A., DeCarlo, C. S., Boitano, L. T., Png, C. Y. M., Patell, R. D., Conrad, M. F., Eagleton, M. J., & Dua, A. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04169-1 · Cited by 357
IL-6: Relevance for immunopathology of SARS-CoV-2
Gubernatorova, E. O., Gorshkova, E. A., Polinova, A. I., & Drutskaya, M. S. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.05.009 · Cited by 346
Special Article - Acute myocardial injury in patients hospitalized with COVID-19 infection: A review
Bavishi, C., Bonow, R. O., Trivedi, V., Abbott, J. D., Messerli, F. H., & Bhatt, D. L. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.05.013 · Cited by 298
Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2
Salamanna, F., Maglio, M., Landini, M. P., & Fini, M. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.594495 · Cited by 298
Datta, P. K., Liu, F., Fischer, T., Rappaport, J., & Qin, X. (2020) · Theranostics · doi:10.7150/thno.48076 · Cited by 262
Cognitive impact of COVID-19: looking beyond the short term
Miners, J. S., Kehoe, P. G., & Love, S. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00744-w · Cited by 261
SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart
Dhakal, B. P., Sweitzer, N. K., Indik, J. H., Acharya, D., & William, P. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.05.101 · Cited by 216
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection
Synowiec, A., Szczepański, A., Barreto-Durán, E., Lie, L. K., & Pyrć, K. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00133-20 · Cited by 228
COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course
Landstra, C. P., & de Koning, E. J. P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.649525 · Cited by 226
The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19
Callender, L. A., Curran, M., Bates, S. M., Mairesse, M., Weigandt, J., & Betts, C. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01991 · Cited by 195
Interrelations between COVID-19 and other disorders
Gasmi, A., Peana, M., Pivina, L. M., Srinath, S., Benahmed, A. G., Semenova, Y. M., Menzel, A., Dadar, M., & Bjørklund, G. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108651 · Cited by 203
Two important controversial risk factors in SARS-CoV-2 infection: Obesity and smoking
Engin, A. B., Engin, A., & Engin, A. (2020) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2020.103411 · Cited by 189
Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19
Bernard, I., Limonta, D., Mahal, L. K., & Hobman, T. C. (2020) · Viruses · doi:10.3390/v13010029 · Cited by 187
Mechanism of inflammatory response in associated comorbidities in COVID-19
de Lucena, T. M. C., Santos, A. F. D. S., de Lima, B. R., Borborema, M. E. D. A., & Silva, J. D. A. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.05.025 · Cited by 186
Zhang, X., Yu, J., Pan, L., & Jiang, H.-Y. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104927 · Cited by 177
Al‐Benna, S. (2020) · Obesity Medicine · doi:10.1016/j.obmed.2020.100283 · Cited by 180
The journey of remdesivir: from Ebola to COVID-19
Pardo, J., Shukla, A. M., Chamarthi, G., & Gupte, A. A. (2020) · Drugs in Context · doi:10.7573/dic.2020-4-14 · Cited by 168
Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality
Que, Y., Hu, C., Wan, K., Hu, P., Wang, R., Luo, J., Li, T., Ping, R., Hu, Q., Sun, Y., et al. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1884248 · Cited by 167
Spiegeleer, A. D., Bronselaer, A., Teo, J., Byttebier, G., Tré, G. D., Belmans, L., Dobson, R., Wynendaele, E., de Wiele, C. V., Vandaele, F., et al. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2020.06.018 · Cited by 166
Cardiac Involvement of COVID-19: A Comprehensive Review
Chang, W., Toh, H. S., Liao, C., & Yu, W. (2020) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2020.10.002 · Cited by 165
Ramarao, P., Joshi, G., & Jagadeesh, G. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109721 · Cited by 160
Understanding the renin–angiotensin–aldosterone–SARS-CoV axis: a comprehensive review
Ingraham, N. E., Barakat, A., Reilkoff, R. A., Bezdicek, T. L., Schacker, T. W., Chipman, J. G., Tignanelli, C. J., & Puskarich, M. A. (2020) · European Respiratory Journal · doi:10.1183/13993003.00912-2020 · Cited by 161
Challenges for Drug Repurposing in the COVID-19 Pandemic Era
Sultana, J., Crisafulli, S., Gabbay, F., Lynn, E., Shakir, S., & Trifirò, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.588654 · Cited by 156
Role of Hypertension on the Severity of COVID-19: A Review
Peng, M., He, J., Xue, Y., Xue, Y., Liu, S., & Gong, Z. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001116 · Cited by 147
Petrariu, O.-A., Barbu, I. C., Niculescu, A.-G., Constantin, M., Grigore, G. A., Cristian, R.-E., Mihăescu, G., & Vrâncianu, C. O. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1296447 · Cited by 155
Risks of ACE Inhibitor and ARB Usage in COVID‐19: Evaluating the Evidence
Sriram, K., & Insel, P. A. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1863 · Cited by 142
Albini, A., Guardo, G. D., Noonan, D. M., & Lombardo, M. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02364-6 · Cited by 138
SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy
Chung, M. K., Karnik, S. S., Saef, J., Bergmann, C. C., Barnard, J., Lederman, M. M., Tilton, J. C., Cheng, F., Harding, C. V., Young, J. B., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102907 · Cited by 138
Mackey, K., King, V. J., Gurley, S. B., Kiefer, M., Liederbauer, E., Vela, K., Sonnen, P., & Kansagara, D. L. (2020) · Annals of Internal Medicine · doi:10.7326/m20-1515 · Cited by 130
Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19
Jarcho, J. A., Ingelfinger, J. R., Hamel, M. B., D’Agostino, R. B., & Harrington, D. P. (2020) · New England Journal of Medicine · doi:10.1056/nejme2012924 · Cited by 126
Baral, R., Tsampasian, V., Dębski, M., Moran, B., Garg, P., Clark, A., & Vassiliou, V. S. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.3594 · Cited by 127
Fodor, A., Tiperciuc, B., Login, C., Orasan, O. H., Lazăr, A.-L., Buchman, C., Hanghicel, P., Sitar-Tăut, A., Suharoschi, R., Vulturar, R., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/8671713 · Cited by 127
Lam, K. W., Chow, K. W., Vo, J. C., Hou, W., Li, H., Richman, P. S., Mallipattu, S. K., Skopicki, H. A., Singer, A. J., & Duong, T. Q. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa447 · Cited by 118
COVID‐19 and diabetes: Is there enough evidence?
Tadić, M., Cuspidi, C., & Sala, C. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.13912 · Cited by 124
COVID‐19 and arterial hypertension: Hypothesis or evidence?
Tadić, M., Cuspidi, C., Grassi, G. M., & Mancia, G. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.13925 · Cited by 116
Pathogenesis, Clinical Manifestations and Complications of COVID-19
Kordzadeh-Kermani, E., Khalili, H., & Karimzadeh, I. (2020) · Future Microbiology · doi:10.2217/fmb-2020-0110 · Cited by 121
Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19?
Feyaerts, A. F., & Luyten, W. H. M. L. (2020) · Nutrition · doi:10.1016/j.nut.2020.110948 · Cited by 110
Scullen, T. A., Keen, J., Mathkour, M., Dumont, A. S., & Kahn, L. W. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.05.192 · Cited by 105
Bottari, B., Castellone, V., & Neviani, E. (2020) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2020.1807475 · Cited by 112
Behl, T., Kaur, I., BUNGAU, S. G., Kumar, A., Uddin, M. S., Kumar, C., Pal, G., Sahil, Shrivastava, K., Zengin, G., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118075 · Cited by 105
COVID-19 and the Vasculature: Current Aspects and Long-Term Consequences
Martínez-Salazar, B., Holwerda, M., Stüdle, C., Piragyte, I., Mercader, N., Engelhardt, B., Rieben, R., & Döring, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.824851 · Cited by 106
COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?
Turco, S. D., Vianello, A., Ragusa, R., Caselli, C., & Basta, G. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.08.039 · Cited by 108
Osman, I. O., Melenotte, C., Brouqui, P., Million, M., Lagier, J., Parola, P., Stein, A., Scola, B. L., Meddeb, L., Mège, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.625732 · Cited by 103
Strodel, B., Olubiyi, O. O., Olagunju, M. O., Keutmann, M., & Loschwitz, J. (2020) · Molecules · doi:10.3390/molecules25143193 · Cited by 100
COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?
Tadić, M., Cuspidi, C., Mancia, G., Dell’Oro, R., & Grassi, G. M. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104906 · Cited by 102
Pasquarelli-do-Nascimento, G., Braz-de-Melo, H. A., Faria, S. S., Santos, I. D. O., Kobinger, G., & Magalhães, K. G. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00530 · Cited by 103
DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?
Valencia, I., Peiró, C., Lorenzo, Ó., Sánchez‐Ferrer, C. F., Eckel, J., & Romacho, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01161 · Cited by 100
Baral, R., White, M., & Vassiliou, V. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00880-6 · Cited by 98
COVID-19 and RAS: Unravelling an Unclear Relationship
D’Ardes, D., Boccatonda, A., Rossi, I., Guagnano, M. T., Santilli, F., Cipollone, F., & Bucci, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21083003 · Cited by 99
Angiotensin II Type I Receptor (AT1R): The Gate towards COVID-19-Associated Diseases
El-Arif, G., Khazaal, S., Farhat, A., Harb, J., Annweiler, C., Wu, Y., Cao, Z., Kovacic, H., Khattar, Z. A., Fajloun, Z., et al. (2022) · Molecules · doi:10.3390/molecules27072048 · Cited by 99
A Bibliometric Network Analysis of Coronavirus during the First Eight Months of COVID-19 in 2020
Furstenau, L. B., Rabaioli, B., Sott, M. K., Cossul, D., Bender, M. S., Farina, E. M. J. D. M., Filho, F. N. B., Severo, P. P., Dohan, M. S., & Bragazzi, N. L. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18030952 · Cited by 96
Pranata, R., Permana, H., Huang, I., Lim, M. A., Soetedjo, N. N. M., Supriyadi, R., Soeroto, A. Y., Alkatiri, A. A., Firman, D., & Lukito, A. A. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.06.047 · Cited by 93
Khera, R., Clark, C. N., Lu, Y., Guo, Y., Ren, S., Truax, B., Spatz, E. S., Murugiah, K., Lin, Z., Omer, S. B., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.018086 · Cited by 95
Grover, A., & Oberoi, M. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa064 · Cited by 89
Interleukin-6 Perpetrator of the COVID-19 Cytokine Storm
Shekhawat, J. K., Gauba, K., Gupta, S., Purohit, P., Mitra, P., Garg, M. K., Misra, S., Sharma, P., & Banerjee, M. (2021) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-021-00989-8 · Cited by 90
Sarzani, R., Giulietti, F., Di Pentima, C., Giordano, P., & Spannella, F. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00189.2020 · Cited by 86
C‐reactive protein as an effector molecule in Covid‐19 pathogenesis
Mosquera-Sulbarán, J., Pedreáñez, A. B., Carrero, Y. N., & Diana Callejas, M. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2221 · Cited by 89
Pirola, C. J., & Sookoian, S. C. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.05.052 · Cited by 84
Narain, S., Stefanov, D. G., Chau, A. S., Weber, A. G., Marder, G. S., Kaplan, B. M., Malhotra, P., Bloom, O., Liu, A., LESSER, M. L., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.09.275 · Cited by 84
Renin-angiotensin-aldosterone system and COVID-19 infection
Alexandre, J., Cracowski, J., Richard, V. J., & Bouhanick, B. (2020) · Annales d Endocrinologie · doi:10.1016/j.ando.2020.04.005 · Cited by 89
Clark, C. E., McDonagh, S. T. J., McManus, R. J., & Martin, U. (2021) · Journal of Human Hypertension · doi:10.1038/s41371-020-00451-x · Cited by 84
Gelman, R., Bayatra, A., Kessler, A., Schwartz, A., & Ilan, Y. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1776161 · Cited by 81
COVID-19 and cardiovascular diseases
Mai, F., Pinto, R. D., & Ferri, C. (2020) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.07.013 · Cited by 78
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs
Bartoli, A., Gabrielli, F., Alicandro, T., Nascimbeni, F., & Andreoné, P. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02569-9 · Cited by 74
Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections
Bonam, S. R., Kotla, N. G., Bohara, R. A., Rochev, Y. A., Webster, T. J., & Bayry, J. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101051 · Cited by 76
COVID-19 pandemic: A review based on current evidence
Medhi, B., Mahalmani, V., Mahendru, D., Semwal, A., Kaur, S., Kaur, H., Sarma, P., & Prakash, A. (2020) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_310_20 · Cited by 72
Wang, Y., Chen, B., Li, Y., Zhang, L., Wang, Y., Yang, S., Xiao, X., & Qin, Q. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26625 · Cited by 72
Liu, X., Long, C., Xiong, Q., Chen, C., Ma, J., Su, Y., & Hong, K. (2020) · Clinical Cardiology · doi:10.1002/clc.23421 · Cited by 73
Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update
Shukla, A. K., & Banerjee, M. (2021) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00439-9 · Cited by 76
Proper Management of People with Obesity during the COVID-19 Pandemic
Lim, S. K., Shin, S. M., Nam, G. E., Jung, C. H., & Koo, B. K. (2020) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes20056 · Cited by 72
Ren, L., Yu, S., Xu, W., Overton, J. L., Chiamvimonvat, N., & Thai, P. N. (2020) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.10.015 · Cited by 68
Ramipril in High-Risk Patients With COVID-19
Amat-Santos, I. J., Santos‐Martínez, S., López‐Otero, D., y, L. N.-F., Gutiérrez, E., del Valle-Fernández, R., Muñoz-García, É., Díaz, V. A. J., Regueiro, A., González-Ferreiro, R., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.040 · Cited by 65
Integrative Network Biology Framework Elucidates Molecular Mechanisms of SARS-CoV-2 Pathogenesis
Kumar, N., Mishra, B., Mehmood, A., Athar, M., & Mukhtar, M. S. (2020) · iScience · doi:10.1016/j.isci.2020.101526 · Cited by 63
Yan, F., Huang, F., Xu, J., Yang, P., Qin, Y., Lv, J., Zhang, S., Ye, L., Gong, M., Liu, Z., et al. (2020) · Cell Discovery · doi:10.1038/s41421-020-00221-6 · Cited by 69
Epithelial and Endothelial Expressions of ACE2: SARS-CoV-2 Entry Routes
Güney, C., & Akar, F. (2021) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps31455 · Cited by 66
Rhee, S. Y., Lee, J.-W., Nam, H., Kyoung, D., Shin, D. W., & Kim, D. J. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0206 · Cited by 64
da Silva, F. R., Guerreiro, R. D. C., Andrade, H. D. A., Stieler, E., Silva, A., & de Mello, M. T. (2020) · Chronobiology International · doi:10.1080/07420528.2020.1756841 · Cited by 63
COVID-19, hipertensión y enfermedad cardiovascular
Salazar, M., Barochiner, J., Espeche, W. G., & Ennis, I. L. (2020) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2020.06.003 · Cited by 69
Iqbal, Z., Ho, J. H., Adam, S., France, M. W., Syed, A. A., Neely, D., Rees, A., Khatib, R., Cegla, J., Byrne, C. D., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.09.008 · Cited by 64
Han, Y., Yuan, K., Wang, Z., Liu, W., Lu, Z.-A., Liu, L., Shi, L., Yan, W., Yuan, J., Li, J., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01629-8 · Cited by 67
Self-citationHypertension and its management in COVID-19 patients: The assorted view
Batiha, G. E., Gari, A. M., Elshony, N., Shaheen, H. M., Abubakar, M. B., Adeyemi, S. B., & Al-Kuraishy, H. M. (2021) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2021.200121 · Cited by 62
Coronary heart disease and COVID-19: A meta-analysis
Liang, C., Zhang, W., Li, S., & Qin, G. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2020.12.017 · Cited by 61
Metadata
- Authors
- Meng, J., Xiao, G., Zhang, J., He, X., Ou, M., Bi, J., Yang, R., Di, W., Wang, Z., Li, Z., Gao, H., Liu, L., & Zhang, G.
- Affiliations
- Southern University of Science and Technology (CN)
- Shenzhen Bay Laboratory (CN)
- Corresponding author
- Gao, Hong
- Liu, Lei
- Zhang, Guoliang
- ORCID
- Venue
- Emerging Microbes & Infections
- Publisher
- Informa UK Limited
- Published
- 2020-01
- Volume
- 9
- Issue
- 1
- Pages
- 757-760
- ISSN
- 2222-1751 (ISSN-L)
- PMC
- PMC7170368
- OpenAlex
- W3013871850
- Cited by
- 619
- References
- 14
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 22 · 2023: 31 · 2022: 61 · 2021: 194 · 2020: 297
- FWCI
- 19.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Emerging Microbes & Infections (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- ImmPort
- Funders
- National Natural Science Foundation of China (81873958)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- COVID-19 pandemic, hypertension, renin-angiotensin system, ACE inhibitors, angiotensin receptor blockers, SARS-CoV-2, interleukin-6, T-cell count, viral load, antihypertensive therapy
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Aged, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, C-Reactive Protein, China, Female, Humans, Hypertension, Male, Middle Aged, Pneumonia, Viral, Renin-Angiotensin System, Retrospective Studies, Interleukin-6, Treatment Outcome, CD3 Complex, Coronavirus Infections, CD8-Positive T-Lymphocytes, Viral Load, Angiotensin II Type 1 Receptor Blockers, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
